{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:03:49Z","timestamp":1785863029142,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015536","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000}}],"reference-count":174,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015536.pub2","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:09:15Z","timestamp":1745305755000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Entecavir for children and adults with chronic hepatitis B"],"prefix":"10.1002","volume":"2025","author":[{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology; Tianjin University; Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitong","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology; Tianjin University; Tianjin China"},{"name":"Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Ma","sequence":"additional","affiliation":[{"name":"Chinese EQUATOR Centre; Hong Kong Baptist University; Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"He","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology; Tianjin University; Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Dong","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology; Tianjin University; Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianling","family":"Shi","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine; Lanzhou University; Lanzhou China"},{"name":"Evidence-based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixuan","family":"Li","sequence":"additional","affiliation":[{"name":"Evidence-based Medicine Center, School of Basic Medical Sciences; Lanzhou University; Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijuan","family":"Yao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xi'an Jiaotong University; Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine; Nanyang Technological University Singapore; Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD015536.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-142-5-200503010-00008","article-title":"Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up","volume":"142","author":"McMahon","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0002|cit2","unstructured":"World Health Organization Hepatitis B http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"issue":"28","key":"10.1002\/14651858.CD015536.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection \u2013 worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"issue":"10003","key":"10.1002\/14651858.CD015536.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"10130","key":"10.1002\/14651858.CD015536.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(18)30499-9","article-title":"The hepatitis B epidemic in China should receive more attention","volume":"391","author":"Chen","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1038\/s41598-017-12005-2","article-title":"Prevalence of chronic hepatitis B and status of HBV care among rural women who planned to conceive in China","volume":"7","author":"Wang","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0007|cit7","unstructured":"World Health Organization Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection apps.who.int\/iris\/bitstream\/handle\/10665\/154590\/9789241549059_eng.pdf"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jhep.2006.03.007","article-title":"Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases","volume":"45","author":"Zarski","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"9791","key":"10.1002\/14651858.CD015536.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD015536.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Global Burden of Disease Liver Cancer Collaboration","year":"2017","journal-title":"JAMA Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/apt.15803","article-title":"Mortality in adults with chronic hepatitis B infection in the United States: a population-based study","volume":"52","author":"Zhou","year":"2020","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0016-5085(72)80047-7","article-title":"Familial clustering of asymptomatic carriers of Australia antigen and patients with chronic liver disease or primary liver cancer","volume":"62","author":"Obayashi","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0015|cit15","unstructured":"World Health Organization Hepatitis: preventing mother-to-child transmission of the hepatitis B virus https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","article-title":"Hepatitis B virus infection in children and adolescents","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterology and Hepatology"},{"issue":"40","key":"10.1002\/14651858.CD015536.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","article-title":"Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review","volume":"20","author":"Sun","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004790.pub2","article-title":"Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers","author":"Lee","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0021|cit21","first-page":"1077","article-title":"The role of entecavir in the treatment of chronic hepatitis B","volume":"3","author":"Dimou","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IDR.S4188","article-title":"Safety and efficacy of entecavir for the treatment of chronic hepatitis B","volume":"4","author":"Osborn","year":"2011","journal-title":"Infection and Drug Resistance"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD015536.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/AAC.42.12.3200","article-title":"In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir","volume":"42","author":"Seifer","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"8","key":"10.1002\/14651858.CD015536.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1742-1241.2011.02719.x","article-title":"Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice","volume":"65","author":"Ridruejo","year":"2011","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1016\/S0168-8278(11)60750-2","article-title":"Outcome of 4-year treatment of entecavir for treatment-na\u00efve chronic hepatitis B","volume":"54","author":"Fung","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(09)60022-2","article-title":"Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients","volume":"50","author":"Tenney","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7150\/ijms.5472","article-title":"Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life","volume":"10","author":"Luo","year":"2013","journal-title":"International Journal of Medical Sciences"},{"issue":"11","key":"10.1002\/14651858.CD015536.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e0224773","DOI":"10.1371\/journal.pone.0224773","article-title":"Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2019","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1111\/hepr.12743","article-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon","year":"2017","journal-title":"Hepatology Research"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.28015","article-title":"Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0036|cit36","first-page":"A66","article-title":"A comparative study of the antiviral efficacy and safety of entecavir versus placebo in HBeAg-positive pediatric subjects with chronic hepatitis B","volume":"33","author":"Bargaje","year":"2014","journal-title":"Indian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0037|cit37","unstructured":"A phase III study of the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection https:\/\/clinicaltrials.gov\/show\/NCT01079806"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.29011","article-title":"CORRECTIONS: randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B","volume":"65","author":"Jonas","year":"2017","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0039|cit39","first-page":"S78","article-title":"A comparative study of the antiviral efficacy and safety of entecavir versus placebo in HBeAg-positive pediatric subjects with chronic hepatitis B","volume":"8","author":"Kelly","year":"2014","journal-title":"Hepatology International"},{"issue":"10","key":"10.1002\/14651858.CD015536.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40258-017-0311-4","article-title":"Economic analysis and budget impact of tenofovir and entecavir in the first-line treatment of hepatitis B virus in Italy","volume":"15","author":"Ruggeri","year":"2017","journal-title":"Applied Health Economics and Health Policy"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bjid.2012.12.005","article-title":"Economic evaluation of treatments for chronic hepatitis B","volume":"17","author":"Wiens","year":"2013","journal-title":"Brazilian Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0043|cit43","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0044|cit44","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0045|cit45","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015536","article-title":"Entecavir for children and adults with chronic hepatitis B","author":"Wu","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0047|cit47","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0048|cit48","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Thomas J Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0049|cit49","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH) ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) http:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0050|cit50","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0052|cit52","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"5","key":"10.1002\/14651858.CD015536.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012069.pub2","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \u2013 assessment of adverse events in non-randomised studies","author":"Storeb\u00f8","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0054|cit54","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0055|cit55","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0056|cit56","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0057|cit57","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0058|cit58","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0059|cit59","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0060|cit60","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jclinepi.2004.09.013","article-title":"Uncertainty method improved on best-worst case analysis in a binary meta-analysis","volume":"58","author":"Gamble","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7211","key":"10.1002\/14651858.CD015536.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7109","key":"10.1002\/14651858.CD015536.pub2-BIB0063|cit63","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0064|cit64","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0065|cit65","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0067|cit67","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"32","key":"10.1002\/14651858.CD015536.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Canadian Medical Association Journal"},{"issue":"8","key":"10.1002\/14651858.CD015536.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive \u2013 Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0072|cit72","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0073|cit73","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017 http:\/\/ctu.dk\/tsa\/learn-more"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0074|cit74","unstructured":"TSA \u2013 Trial Sequential Analysis Copenhagen Trial Unit 2021"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0077|cit77","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0078|cit78","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"12","key":"10.1002\/14651858.CD015536.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.cgh.2021.11.032","article-title":"Entecavir prevents HBV reactivation during direct acting antivirals for HCV\/HBV dual infection: a randomized trial","volume":"20","author":"Cheng","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"602A","DOI":"10.1002\/hep.32188","article-title":"Role of entecavir in preventing clinical reactivation of HBV in HCV\/HBV co-infected patients receiving DAA therapy for chronic hepatitis C","volume":"74","author":"Cheng","year":"2021","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0081|cit81","unstructured":"NUC in preventing HBV reactivation in HCV\/HBV co-infected patients receiving DAA for CHC https:\/\/clinicaltrials.gov\/show\/NCT04405011"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/jhep.2001.26815","article-title":"Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection","volume":"34","author":"De Man","year":"2001","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD015536.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jvh.13608","article-title":"Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study","volume":"28","author":"Erken","year":"2021","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0084|cit84","first-page":"442A","article-title":"Safety and antiviral effect of the farnesoid x receptor agonist EYP001 in chronic hepatitis B patients: a randomised placebo-controlled phase 1b study","volume":"70","author":"Erken","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD015536.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jfma.2017.12.007","article-title":"Phase IV randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B","volume":"117","author":"Hsu","year":"2018","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0086|cit86","unstructured":"A study of PEGASYS (peginterferon alfa-2a (40KD)) in combination with adefovir or entecavir in patients with HBeAg-positive chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT00922207"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0168-8278(14)60115-X","article-title":"Combination therapy with peginterferon alfa-2alpha and a nucleos(T)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study","volume":"60","author":"Su","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0088|cit88","first-page":"109","article-title":"Effectiveness of entecavir or tenofovir in eradicating chronic hepatitis B infection in patients with superimposed acute hepatitis A \/ E virus infection","volume":"26","author":"Humayun","year":"2018","journal-title":"Journal of Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD015536.pub2-BIB0089|cit89","first-page":"1511","article-title":"Diwu Yanggan capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial","volume":"10","author":"Li","year":"2018","journal-title":"American Journal of Translational Research"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0090|cit90","unstructured":"A clinical study on Diwuyanggan capsule in treating HBeAg-negative chronic hepatitis B https:\/\/www.chictr.org.cn\/showprojEN.html?proj=6593"},{"issue":"5","key":"10.1002\/14651858.CD015536.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0092|cit92","first-page":"315A","article-title":"Tenofovir disoproxil fumarate alone or in combination with entecavir in patients with entecavir-resistant chronic hepatitis B: multicenter randomized trial","volume":"61","author":"Lim","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1007\/s12072-016-9783-9","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for entecavir-resistant chronic hepatitis B","volume":"11","author":"Gwak","year":"2017","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0094|cit94","unstructured":"Tenofovir vs. tenofovir plus entecavir in entecavir-resistant chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT01639092"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1007\/s12072-016-9707-8","article-title":"Tenofovir monotherapy up to 96-weeks in patients with adefovir resistant chronic hepatitis B","volume":"10","author":"Lim","year":"2016","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1016\/S0168-8278(14)61224-1","article-title":"Randomized trial of tenofovir monotherapy versus tenofovir plus entecavir combination therapy in chronic hepatitis B patients with genotypic resistance mutations to adefovir","volume":"60","author":"Lim","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1007\/s12072-016-9783-9","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for adefovir-resistant chronic hepatitis B","volume":"11","author":"An","year":"2017","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0099|cit99","unstructured":"Tenofovir plus entecavir vs. tenofovir in adefovir-resistant chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT01639066"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1097\/QAI.0b013e3182303937","article-title":"Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia","volume":"58","author":"Luetkemeyer","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0101|cit101","unstructured":"Entecavir intensification for persistent HBV viremia in HIV-HBV infection https:\/\/clinicaltrials.gov\/study\/NCT00662545"},{"issue":"14","key":"10.1002\/14651858.CD015536.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1097\/QAD.0b013e32830b3ab5","article-title":"Efficacy and safety of entecavir for chronic HBV in HIV\/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy","volume":"22","author":"Pessoa","year":"2008","journal-title":"AIDS"},{"issue":"14","key":"10.1002\/14651858.CD015536.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.4103\/0366-6999.235880","article-title":"Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in hepatitis B e antigen-positive hepatitis B patients: a randomized, multicenter, phase IIIb open-label study (POTENT study)","volume":"131","author":"Jun","year":"2018","journal-title":"Chinese Medicine Journal"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0104|cit104","unstructured":"Efficacy study of sequential therapy of peginterferon alfa-2a following entecavir in patient with chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT01220596"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/jvh.12467","article-title":"A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: role of host and viral factors associated with treatment response","volume":"23","author":"Tangkijvanich","year":"2016","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0106|cit106","first-page":"S179","article-title":"The association of interferon gamma induced protein 10 (IP 10) polymorphism and treatment response to pegylated interferon in patients with HBeAg negative chronic hepatitis B","volume":"9","author":"Limothai","year":"2015","journal-title":"Hepatology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0107|cit107","first-page":"S178","article-title":"Single nucleotide polymorphism of HLA DPA1 is associated with treatment response to pegylated interferon in Thai patients with HBeAg negative chronic hepatitis B","volume":"9","author":"Limothai","year":"2015","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0108|cit108","unstructured":"Pegylated interferon alpha-2b monotherapy versus combination with entecavir in HBeAg-negative chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT01243281"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0109|cit109","first-page":"S239","article-title":"Interim analysis of randomized study comparing efficacy of peginterferon-alpha-2b monotherapy versus combination with entecavir in HBeAg-negative chronic hepatitis B","volume":"7","author":"Tangkijvanich","year":"2013","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0110|cit110","first-page":"S70","article-title":"A randomized study comparing efficacy of peginterferon-alpha-2b monotherapy versus combination with entecavir in HBeAg negative chronic hepatitis B: analysis of week 72","volume":"8","author":"Tangkijvanich","year":"2014","journal-title":"Hepatology International"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0111|cit111","first-page":"S204","article-title":"A randomized study comparing efficacy of peginterferon alpha 2b monotherapy versus combination with entecavir in HBeAg negative chronic hepatitis B","volume":"9","author":"Tangkijvanich","year":"2015","journal-title":"Hepatology International"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31854-8","article-title":"Kinetics of serum HBsAg and HBcrAg in predicting response to pegylated interferon-based therapy in patients with HBeAg negative chronic hepatitis B","volume":"66","author":"Chuaypen","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD015536.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3851\/IMP2754","article-title":"Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study","volume":"19","author":"Tseng","year":"2014","journal-title":"Antiviral Therapy"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0115|cit115","unstructured":"Entecavir for chronic hepatitis B patients with persistently normal ALT https:\/\/clinicaltrials.gov\/show\/NCT01833611"},{"issue":"12","key":"10.1002\/14651858.CD015536.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \"e\" antigen-positive chronic hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0117|cit117","unstructured":"A study of PEGASYS (peginterferon alfa-2a (40KD)) plus entecavir in treatment-naive patients with HBeAg-positive chronic hepatitis B https:\/\/clinicaltrials.gov\/show\/NCT00614471"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12072-007-9016-3","article-title":"Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China","volume":"1","author":"Yao","year":"2007","journal-title":"Hepatology International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015536.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/S1386-6532(06)80272-6","article-title":"Entecavir results in a rapid reduction in viral load in chronic hepatitis B patients who have failed lamivudine therapy: a randomized, placebo-controlled study in China","volume":"36","author":"Yao","year":"2006","journal-title":"Journal of Clinical Virology"},{"issue":"S2","key":"10.1002\/14651858.CD015536.pub2-BIB0120|cit120","first-page":"A127","article-title":"Entecavir (ETV) results in early viral load reduction in chronic hepatitis B (CHB) patients who have failed lamivudine (LVD) therapy: a randomized, placebo-controlled study in China (study ETV-056)","volume":"21","author":"Yao","year":"2006","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0121|cit121","first-page":"674A","article-title":"A randomized, placebo-controlled study (ETV-056) in China of the efficacy and safety of entecavir in chronic hepatitis B patients who have failed lamivudine","volume":"40","author":"Yao","year":"2004","journal-title":"Hepatology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0122|cit122","first-page":"S193","article-title":"Entecavir results in early viral load reduction in chronic hepatitis B patients who have failed lamivudine therapy: a randomized, placebo-controlled study in China","volume":"44","author":"Yao","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD015536.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.19193\/0393-6384_2021_6_535","article-title":"The effect of artificial liver plasma diafiltration combined with entecavir on short-term curative effect, liver function, and HBV-DNA negative conversion rate in the treatment of chronic subacute liver failure","volume":"37","author":"Zeng","year":"2021","journal-title":"Acta Medica Mediterranea"},{"issue":"5","key":"10.1002\/14651858.CD015536.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3760\/cma.j.issn.1007-3418.2009.05.008","article-title":"Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area","volume":"17","author":"Li","year":"2009","journal-title":"Chinese Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12072-009-9123-4","article-title":"Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area","volume":"9","author":"Li","year":"2009","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0126|cit126","first-page":"13","article-title":"Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment","volume":"15","author":"Wang","year":"2007","journal-title":"Chinese Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0127|cit127","first-page":"165","article-title":"Efficacy comparison of rescue therapies between TDF monotherapy and TDF-ETV combination therapy in CHB patients who failed to be rescued with ETV","volume":"21","author":"Li","year":"2016","journal-title":"Chinese Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0128|cit128","first-page":"589","article-title":"Effects of entecavir on serum HBV DNA load and transformer growth factor-\u03b2(1) in patients with chronic hepatitis B","volume":"32","author":"Xiao","year":"2012","journal-title":"Journal of Southern Medical University"},{"issue":"7","key":"10.1002\/14651858.CD015536.pub2-BIB0129|cit129","first-page":"484","article-title":"A study of the dosage and efficacy of entecavir for treating hepatitis B virus","volume":"13","author":"Yao","year":"2005","journal-title":"Chinese Journal of Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"711A","DOI":"10.1016\/S0270-9139(03)81190-4","article-title":"A phase II study in China of the safety and antiviral activity of entecavir in adults with chronic hepatitis B infection","volume":"38","author":"Yao","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0131|cit131","first-page":"115","article-title":"Efficacy of peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads","volume":"27","author":"Zeng","year":"2013","journal-title":"Chinese Journal of Experimental and Clinical Virology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0132|cit132","first-page":"S250","article-title":"Efficacy of peginterferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high viral loads","volume":"13","author":"Liu","year":"2013","journal-title":"Hepatology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1007\/s12072-016-9707-8","article-title":"Co-treatment with pegylated interferon alfa 2a and entecavir for hepatitis D: a randomized trial","volume":"10","author":"Abbas","year":"2016","journal-title":"Hepatology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0134|cit134","first-page":"5","article-title":"Entecavir (ETV) treatment through 96 weeks results in virologic and biochemical improvement in HBeAg (-) chronic hepatitis B patients (study ETV-027)","volume":"26","author":"Akarca","year":"2006","journal-title":"Liver International"},{"issue":"4 (Pt 2)","key":"10.1002\/14651858.CD015536.pub2-BIB0135|cit135","first-page":"300A","article-title":"Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine","volume":"36","author":"Chang","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"S674","DOI":"10.1007\/s12072-016-9783-9","article-title":"To research the antiviral treatment of low grade chronic hepatitis B associated with tuberculosis patients (82 cases contrast analysis)","volume":"11","author":"Cheng","year":"2017","journal-title":"Hepatology International"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0137|cit137","unstructured":"A treatment strategy research of chronic hepatitis B based on the central immune organs trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IOR-14005266"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0138|cit138","unstructured":"Evaluation of the pharmacokinetics, safety, tolerability and efficacy of entecavir (ETV) in pediatric subjects with chronic hepatitis B virus (HBV) infection who are HBeAg-positive. Revised protocol 02, incorporating protocol amendment 01 (v1.0, date 18-Apr-2008), and protocol amendment 04 (v1.0, date 05-Dec-2008) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-005816-26-BE"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015536.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1043A","DOI":"10.1002\/hep.24666","article-title":"Efficacy and safety of entecavir monotherapy versus standard of care in chronic hepatitis B: 2-year interim single centre report of the REALM study","volume":"54","author":"Lu","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0140|cit140","first-page":"340A","article-title":"Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy","volume":"34","author":"Tasopoulos","year":"2001","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD015536.pub2-BIB0141|cit141","first-page":"1365","article-title":"Early results of entecavir associated with kushenin in treating chronic type B hepatitis in 41 patients","volume":"38","author":"Wang","year":"2009","journal-title":"Shanxi Medical Journal"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"620230","DOI":"10.1155\/2013\/620230","article-title":"Lingmao formula combined with entecavir for HBeAg-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2013","author":"Zhu","year":"2013","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0143|cit143","unstructured":"A study of the clinical manifestation and the therapy of chronic hepatitis B combining traditional Chinese with Western medicine www.chictr.org.cn\/showprojEN.html?proj=8941"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S0168-8278(09)60353-6","article-title":"The changes of intrahepatic cccDNA during entecavir or adefovir dipivoxil treatment for chronic hepatitis B patients","volume":"50","author":"Cheng","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S606","DOI":"10.1016\/S0168-8278(16)01120-X","article-title":"Switching tenofovir disoproxil fumarate (TDF) plus entecavir combination therapy to TDF monotherapy is safe and efficacious in patients with multiple drug resistant chronic hepatitis B: randomized trial","volume":"64","author":"Lim","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.29187","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial","volume":"66","author":"Lim","year":"2017","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S693","DOI":"10.1016\/S0168-8278(17)31860-3","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hepatitis B","volume":"66","author":"Kwon","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","article-title":"Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trial","volume":"71","author":"Lim","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"245A","DOI":"10.1002\/hep.30257","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: results of 5-year clinical trial","volume":"68","author":"Choi","year":"2018","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1007\/s12072-019-09936-5","article-title":"Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: results of 5-year clinical trials","volume":"13","author":"Choi","year":"2019","journal-title":"Hepatology International"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S0618-8278(19)30910-7","article-title":"No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy","volume":"70","author":"Choi","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015536.pub2-BIB0152|cit152","first-page":"S232","article-title":"Combination therapy of adefovir and entecavir is effective in CHB patients with a suboptimal virological response to adefovir monotherapy","volume":"7","author":"Li","year":"2013","journal-title":"Hepatology International"},{"issue":"8","key":"10.1002\/14651858.CD015536.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3760\/cma.j.issn.1007-3418.2013.08.004","article-title":"Dynamic change of hepatitis B surface antigen expression in chronic hepatitis B patients during the natural recovery course and the short-term antivirus treatment","volume":"21","author":"Liu","year":"2013","journal-title":"Chung Hua Kan Tsang Ping Tsa Chih"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0154|cit154","first-page":"90","article-title":"The efficacy of entecavir treatment for chronic hepatitis B patients with acute liver failure","volume":"3","author":"Shu","year":"2009","journal-title":"Hepatology International"},{"issue":"2","key":"10.1002\/14651858.CD015536.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.intimp.2015.06.019","article-title":"Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection","volume":"27","author":"Wei","year":"2015","journal-title":"International Immunopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015536.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/S0168-8278%2812%2960539-X","article-title":"Lamivudine and entecavir treatment in patients with chronic hepatitis B liver failure: a large, multicenter, placebo controlled, prospective study in China","volume":"56","author":"Yang","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"e132684","DOI":"10.5812\/hepatmon-132684","article-title":"Effects of entecavir on serum hepatitis B virus-DNA, interferon-\u03b3, and pregenomic RNA in patients with chronic hepatitis B virus infection","volume":"23","author":"Gong","year":"2023","journal-title":"Hepatitis Monthly"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0158|cit158","unstructured":"Entecavir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-C000000393"},{"issue":"4","key":"10.1002\/14651858.CD015536.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11596-017-1771-3","article-title":"Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B","volume":"37","author":"Li","year":"2017","journal-title":"Journal of Huazhong University of Science and Technology"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1517\/14740338.2012.653340","article-title":"Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901","volume":"11","author":"Manns","year":"2012","journal-title":"Expert Opinion on Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0161|cit161","first-page":"205","article-title":"Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure","volume":"24","author":"Hu","year":"2010","journal-title":"Chinese Journal of Experimental & Clinical Virology"},{"issue":"Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"422A","DOI":"10.1002\/hep.23301","article-title":"Lamivudine and entecavir significantly improved the prognosis of early-and midstage hepatitis B related acute on chronic liver failure - a prospective, randomized, open and parallel controlled clinical trial","volume":"50","author":"Hu","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD015536.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"1086A","DOI":"10.1002\/hep.23995","article-title":"Study on entecavir regulating cellular immune of patients with acute on chronic hepatitis B liver failure: a randomized controlled trial","volume":"52","author":"Lin","year":"2010","journal-title":"Hepatology"},{"issue":"S2","key":"10.1002\/14651858.CD015536.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"A112","DOI":"10.1111\/j.1440-1746.2009.06464.x","article-title":"The analysis of early virologic response in combination treatment with pegylated interferon and nucleos(t)ide analogue in patients with chronic hepatitis B","volume":"25","author":"Moon","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"19","key":"10.1002\/14651858.CD015536.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"10.1002\/14651858.CD015536.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"k1382","DOI":"10.1136\/bmj.k1382","article-title":"Do direct acting antivirals cure chronic hepatitis C?","volume":"361","author":"Jakobsen","year":"2018","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Medicine"},{"issue":"9","key":"10.1002\/14651858.CD015536.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1016\/j.clinthera.2017.07.015","article-title":"Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir: a systematic review and meta-analysis","volume":"39","author":"Chen","year":"2017","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-naive chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015536.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.28278","article-title":"Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD015536.pub2-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011645.pub2","article-title":"Pharmacological interventions for acute hepatitis B infection","author":"Mantzoukis","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:02:49Z","timestamp":1785859369000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015536.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":174,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015536.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}